Search
Davanat
go.drugbank.com/drugs/DB15311InvestigationalDavanat is under investigation in clinical trial NCT00054977 (Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors).
Heparin, bovine
go.drugbank.com/drugs/DB15404InvestigationalHeparin, bovine is under investigation in clinical trial NCT01072747 (Efficacy And Safety Of Unfractionated Heparin In Patients With Cardiovascular Surgery Using Cardiopulmonary Bypass).
RS5441
go.drugbank.com/drugs/DB33178ExperimentalRS5441, also known as ET-02, is a small molecule topical medication investigated for male pattern baldness and age-related alopecia.[L57508, L57509]
Ifetroban
go.drugbank.com/drugs/DB12321InvestigationalIfetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.
Filaminast
go.drugbank.com/drugs/DB02660ExperimentalAs such, has potential in the treatment of asthma and chronic obstructive pulmonary disease (COPD).
Clinafloxacin
go.drugbank.com/drugs/DB14025ExperimentalHowever, its approval and release have been halted due to the presence of serious side effects.
TT 173
go.drugbank.com/drugs/DB17717InvestigationalTT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental
Zirconium panitumumab Zr-89
go.drugbank.com/drugs/DB19228InvestigationalZirconium panitumumab Zr-89 is under investigation in clinical trial NCT05423197 (Study Evaluating Zr-panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous
5-deoxyflavanone
go.drugbank.com/drugs/DB03601ExperimentalThese are compounds containing a flavan-3-one moiety, whose structure is characterized by a 2-phenyl-3,4-dihydro-2H-1-benzopyran bearing a ketone at the carbon C3.
Irampanel
go.drugbank.com/drugs/DB21123InvestigationalIrampanel is under investigation in clinical trial NCT02222961 (Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers).